BD (Becton, Dickinson and Company), a global leader in medical technology, has announced the initiation of the first pharma-sponsored clinical trial utilizing the BD Libertas™ Wearable Injector for subcutaneous delivery of complex biologic drugs. This trial marks a significant step towards enhancing patient care by potentially converting infused medications that require hospital visits to more convenient self-injection options at home. The BD Libertas™ Wearable Injector, which has been validated through over 50 pre-clinical and clinical studies conducted by BD, offers a fully mechanical, patient-ready design with a straightforward "peel, stick and click" mechanism. The results of this trial have not yet been presented. For further information on the BD Libertas™ Wearable Injector and its capabilities, interested parties are directed to visit BD's official website.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.